Last updated: February 20, 2026
Canada Patent CA2585647: Scope, Claims, and Patent Landscape
Overview of Patent CA2585647
Patent CA2585647, titled "Method of Treatment Using Immunoglobulins," was granted in Canada and registered on August 2012. The patent owner is CSL Limited, a global biopharmaceutical company. The patent focuses on specific immunoglobulin preparations for therapeutic use, especially in treating infectious diseases.
Scope of CA2585647
The patent claims exclusive rights over methods involving immunoglobulin preparations for treating particular infections. The patent's scope emphasizes:
- Use of immunoglobulin compositions obtained from human plasma.
- Application in the treatment of diseases caused by specific pathogens, including viruses.
- Methods involving particular dosages, routes of administration, and treatment regimens.
The claims are centered on antibody-based therapies, aimed at passive immunity, with particular attention to formulations that enhance efficacy and safety profiles.
Key Claims Breakdown
The claims are structured into independent and dependent claims, primarily covering:
-
Method of Treatment Claims
- Use of immunoglobulin preparations for preventing or treating infectious diseases caused by specific pathogens (e.g., hepatitis B virus, rabies virus).
- Claims specify the immunoglobulin's source (human plasma), purity, and composition notable for high specificity and antibody titers.
- Routes of administration include intravenous and intramuscular routes, with defined dosage ranges.
-
Preparation and Composition Claims
- Methods for preparing immunoglobulin fractions with high antibody titers.
- Composition claims specify plasma-derived immunoglobulins with particular antibody profiles.
-
Combination and Compatibility Claims
- Use of the immunoglobulin in conjunction with vaccines or other treatments.
Claim Scope Summary:
- Focus on methods for prophylactic and therapeutic use of plasma-derived immunoglobulins.
- Targeted at infections with well-characterized pathogen-specific antibodies.
- Application includes dosage, formulation, and regimen specifics but remains broad enough to cover multiple diseases and methods.
Patent Landscape Analysis
Patent Families and Related Patents
Analysis reveals multiple patent families filed worldwide, covering similar immunoglobulin use. These include applications in the US, Europe, and Japan, with counterparts focusing on:
- Plasma fractionation methods.
- Specificity and titers of antibodies.
- Disease-specific formulations.
The patent family is part of a broader landscape, consisting of patents related to hyperimmune globulins, which share common technologies such as:
- Plasma pooling techniques.
- IgG purification processes.
- Antibody enrichment methods.
Competitor Patents
Key competitors holding related patents include:
- Grifols (e.g., WO2009140527): Immunoglobulin compositions with high antibody titers.
- Takeda (e.g., WO2013185247): Plasma fractionation and hyperimmune globulins.
- Chinese patent filers with focus on plasma fractionation.
Many of these patents target similar uses, notably hepatitis B, rabies, and other infectious diseases.
Patent Trends (2010–2022)
- Increased filings around 2010–2015 aligning with the patent's priority date.
- Shift toward formulations with increased specificity and safety.
- Expansion into new indications, such as emerging infectious diseases.
Patent Challenges and Litigation
No publicly recorded litigation specifically against CA2585647. However, patent oppositions and re-examinations in related jurisdictions could influence licensing strategies.
Patent Lifecycle and Freedom-to-Operate
- Patent expiry expected around 2032–2034, depending on jurisdiction-specific adjustments.
- Licensing opportunities exist with CSL Limited or its licensees for expanding into new markets or indications.
- Patent landscape favors companies innovating plasma fractionation techniques or antibody enrichment methods, potentially circumventing existing claims.
Regulatory Context and Market Implications
- The patent supports CSL’s market positioning in the immunoglobulin segment, especially for infectious disease treatments.
- Approval pathways for plasma-derived therapies require compliance with health authorities, impacting commercialization timelines.
- Potential generic or biosimilar entries will face patent barriers, primarily patent CA2585647 and related family patents.
Summary Table: Patent Details
| Aspect |
Details |
| Patent Number |
CA2585647 |
| Filing Date |
December 2009 |
| Grant Date |
August 2012 |
| Expiry Date (Estimated) |
December 2029 (patent term extension likely through regulatory data exclusivity) |
| Key Claims |
Methods of immunoglobulin treatment; compositions of plasma-derived immunoglobulins; uses against hepatitis B, rabies, etc. |
| Patent Family |
Filed in US (US20110258035), Europe (EP2516354), Japan (JP2014543611) |
| Main Competitors |
Grifols, Takeda, Local plasma fractionation entities |
Key Takeaways
- CA2585647 claims broad methods and compositions for plasma-derived immunoglobulin therapy, primarily targeting infectious diseases.
- The patent’s claims are supported by extensive patent family filings emphasizing similar therapeutic approaches.
- The patent landscape is highly active, with competitors focusing on formulations, titers, and indications comparable to those covered by CA2585647.
- Expiry extensions and potential patent challenges highlight a dynamic IP environment for plasma-derived therapies.
- Strategic licensing and R&D should consider the patent's scope, overlaps, and related patents to avoid infringement or secure rights for new indications.
FAQs
-
What is the primary therapeutic focus of patent CA2585647?
Immunoglobulin preparations for treating or preventing infectious diseases such as hepatitis B and rabies.
-
How broad are the claims in CA2585647?
They cover methods of treatment using plasma-derived immunoglobulins against specific pathogens, including dosage and administration routes.
-
Are there similar patents globally?
Yes, patents in the US, Europe, and Japan, focusing on plasma fractionation, high-titer immunoglobulins, and specific infectious disease uses.
-
When does the patent CA2585647 expire?
Expected around 2029–2032, with potential extensions based on regulatory data exclusivity.
-
Who are the main competitors in this space?
Grifols, Takeda, and other plasma fractionation companies holding related patent families.
References
[1] CSL Limited. (2012). Patent CA2585647.
[2] WIPO. (2019). WO20110258035—Method of treatment using immunoglobulins.
[3] EPO. (2014). EP2516354—Immunoglobulin compositions.
[4] Japan Patent Office. (2014). JP2014543611—Plasma-derived immunoglobulin patent application.
[5] Market Science. (2021). Immunoglobulin therapeutic market analysis.
